← Leaderboards
C Jeffrey Brinker
University Of New Mexico Health Scis Ctr
$2,079,432
Attributed
$6,176,374
Total exposure
3
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $734.1K · FY2010–22$1M$750K$500K$250K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$6,176,374 · 3
By mechanism
R01$4,446,713 · 2
U01$1,729,661 · 1
Top collaborators
- Wadih Arap5 shared
- Vittorio Cristini5 shared
- Renata Pasqualini5 shared
- Cheryl L Willman5 shared
- Eric G Jakobsson4 shared
- Stanley R. Maloy4 shared
Most similar at University Of New Mexico Health Scis Ctr
Same institution · by research overlap
- Bryce C Chackerian$17,300,500
Others in their field
Top investigators on “Proteins”
- David Heimbrook · Leidos Biomedical Research, Inc.$354,061,551
- Randall J Bateman · Washington University$187,292,085
- Paul S. Aisen · Cognition Therapeutics, Inc.$175,382,342
- Reisa A. Sperling · Banner Health$145,046,481
- Barton F Haynes · Duke University$136,029,850
- Joseph L Goldstein · University Of Texas Sw Med Ctr/Dallas$102,433,280
Research focus
ProteinsCellsDesignResistanceEngineeringCancer TherapySurfaceBaseNanocarrierEncapsulatedInsightDrug KineticsNanomedicineImageConfocal MicroscopyBiodistributionLipid BilayersIn VivoInterestChemistryComplexDoxorubicinDrug Delivery SystemsIn Vitro
Grant awards (14)
A Targeted Nanomedicine Prototype Against Enzalutamide-resistant Prostate Cancer$629,467
R01 · FY2022 · CA
A Targeted Nanomedicine Prototype Against Enzalutamide-resistant Prostate Cancer$642,358
R01 · FY2021 · CA
A Targeted Nanomedicine Prototype Against Enzalutamide-resistant Prostate Cancer$642,804
R01 · FY2020 · CA
A Targeted Nanomedicine Prototype Against Enzalutamide-resistant Prostate Cancer$623,916
R01 · FY2019 · CA
A Targeted Nanomedicine Prototype Against Enzalutamide-resistant Prostate Cancer$673,092
R01 · FY2018 · CA
Peptide-directed protocells and virus-like particles-new nanoparticle platforms f$322,235
U01 · FY2014 · CA
Genetically Specific Therapy Against Pathogenic Bacteria$152,395
R01 · FY2014 · GM
Genetically Specific Therapy Against Pathogenic Bacteria$367,653
R01 · FY2013 · GM
Peptide-directed protocells and virus-like particles-new nanoparticle platforms f$321,220
U01 · FY2013 · CA
Genetically Specific Therapy Against Pathogenic Bacteria$380,988
R01 · FY2012 · GM
Peptide-directed protocells and virus-like particles-new nanoparticle platforms f$353,085
U01 · FY2012 · CA
Peptide-directed protocells and virus-like particles-new nanoparticle platforms f$371,721
U01 · FY2011 · CA
Genetically Specific Therapy Against Pathogenic Bacteria$334,040
R01 · FY2011 · GM
Peptide-directed protocells and virus-like particles-new nanoparticle platforms f$361,400
U01 · FY2010 · CA